IMC Titanium Stent long life reasonable cost IMC International - - PowerPoint PPT Presentation

1

IMC Titanium Stent

long life reasonable cost

IMC – International Medical Contrivances

2

IMC – International Medical Contrivances

Type : Titanium Oxynitride Coating Stent Platform :

316 L Stainless steel alloy

• r

L605 Cobalt Chromium Alloy

Technology :Single Layer Physical Vapor Deposition

PVD coating, patented by IMC.

• Product could be based either on :
• a OEM Stent design, already tested and approved,
• Or a new stent design to finalize the development and

approval.

The new developed type of Titaniumoxinitrid is not consumed, it creates a biocompatible permanent coating

IMC Cardiovascular Stent

3

IMC – International Medical Contrivances

 Product could be based either on :

• an OEM classic Stent, already tested and

approved,

• r based on a new stent design subject to

development and approval.

4

 Bare Metal Stents BMS  Drug Eluting Stents DES  Other Titanium Oxide nitride coated stents with multiple layer coating Bare Metal Stents BMS induce a metallic foreign body reaction, which can be avoided by the use of titanium nitride

• xide coating and decrease the Restenosis & thrombosis

rates

• main drawbacks of BMS
• High late loss
• high rate of thrombosis
• adverse reactions

IMC

Types of Stents

5

Any DES Stent becomes after eluting the drug components a BMS Stent , approximately 9 months Main drawbacks, worst to BMS :

• unexplained late thrombosis
• Negative Late loss
• Patient under life time medication ( cost and side

effects) High cost for the patient & the insurance for Abbot Stent p.e. cost of medication is about 2200 USD per year

• Ineffective drug elution and no possible process of stent

endothelization

 Hexacath



Multilayer with constant stoichometry



Total thickness 250nm



RF- Magnetron Sputtering



Energy of particles 2-12eV



Substrate penetration 0,05nm



Nine coating interfaces



Desctructive quality control 10%



Coating uniformity +/-20%



Time per coating run 90min  IMC Titanium Stent



Single layer with varying stoichometry



Total thickness max 50nm



Filtered Arc Deposition RF Magnetron



180 -200eV



1-2nm



One interface



Less than 2%



+/- 5%



45 min

6

7

 Enhanced Stent Bioactivity and Biocompatibility

in synergy with an improved stent coating Biomechanics

The new technology is patented through

 EP 249 1161

&

 Eurasia patent 201200502  other countries pending  IMC International Medical Contrivances SA, is

• wning the IP- rights, and supporting the

development of this new technology

8

9

10

11

12

Exemple : coupe à travers une artère après l’implantation d’un stent (points noirs). Une couche protectrice de cellules s’est déjà formée au-dessus du stent.

13

Source : « Stents coronariens biorésorbables : une révolution ? », F. Koegler, E. De Benedett, Rev Med Suisse 2013 ; 9 : 775-8

14

CON ONCEPT EPT:

Locally produce the Stent in key markets under a license for the use of the Patent and to transfer the know how to the Licensee´s personnel. IMC will build for the client a modular Production Line; that can after the completion of training and start up, be simply relocated .

To To ac achieve ieve this: s:

IMC offers to set up the production line in Switzerland in a modular system, tailor made to client´s needs and a 6 Months to one year training and know how transfer to the personnel selected by the client. Thereafter the modular production line can be transferred to the country of destination Stent production will be accompanied by the specialists under the License Agreement

IMC C has develo veloped ped th the e new ew sten tent t coat

• atin

ing g te tech chnolo logy gy to toget gether her with th leadin ading g specialis ecialists s in the indu dustry try

 Turn key modular coating facility for the new

generation IMC Titanium Stent

 Training and know how transfer for your personnel  Patent- License for your target market  Ongoing technical and production support  Scientific data and regulatory support for the local

approvals of the stents

The training is offered by a team of professionals working with IMC, well acquainted with the patent and with many years experience in the industry

15

HARDWARE; PATENT –LICENSE SE; KNOW-HOW

Dr. . Joha hann nn La Lamm mmer er

• 1972 Dr. phil.

. In Physi ysics cs at the Univer iversity sity Graz z Austria ria

• Since

ce 1973 speci cialize alized d in surfa face ce treatment tment and d co coat ating ng tec echnology nology

• Univer

iversity sity of Lausan sanne ne

• LSHR

HR ( L Labora

• ratoir

toire Suisse se de rech charge arge horloger

• gere)
• Inventor

nventor of the e co coat atings ngs for the e Hex exacath acath Stents ents

• Inve

nventor ntor and superv ervisor sor of the technol chnological

• gical

applicat ication ion for the new IMC C Stent

16

Dr. . M Mustapha tapha Mekki

• PhD in Chemistry , University of Geneva
• R&D Project Management in leading stent

developments

• Project Leader and Production Manager of
• ne of the main European stent producers
• Biomaterials Lab Researcher University of

Geneva

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

IMC IMC SPV TRUSTEE STEE Buyer

Guarantee ee wi with shares es Share e sales agreem ement ent with option

• n for asset deal

upon pon completio tion of

• f

training License se agreem emen ent

IMC IMC SPV TRUSTEE STEE Buyer

License se agreem ement ent for patent t & know know how how

Producti ction

• n line

Selec ect t and send d person sonnel nel for training Credit line for equipment ent & & training cost Instruc ructo tors rs & & Specialist sts Supplies es OEM producer cer

IMC IMC SPV Buyer Producti ction

• n line

Opera rati ting ng company ny

License nse

IMC IMC SPV

License se agreem emen ent for patent Instruc ructo tors rs & & Specialists sts Supplies es OEM producer cer

Buyer

Share e purchase se agreem emen ent

 IMC sets up

up the SPV V in Geneva eva Switzer tzerland land

 You enter into a

a sales purchase chase agreemen ement, , gran anting ting yo you the irrev evocable cable option ion for a a shar are or

• r

an asset deal after r the comp mpleti etion

• n of
• f the traini

ning ng

 SPV obta

taine ines Patent nt and Know

• w How lice

cense nse for yo your tar arget et mar arket ket

 SPV acq

cquir uires es the steril il room

• m faci

ciliti lities es and the equipm pment nt requir ired ed, , financ nced ed by by yo you.

 You ar

are sec ecured red through

• ugh a

a trustee stee arrangement gement with a a swiss trustee tee jointly tly selected cted

37

 IMC coordinates for SPV all arrangements

with all relevant suppliers

 After successful basis-training –>production

starts

 When standards are achieved -> SPV may

starts selling the stents

 Training is continued until your crew is able

to produce the product without supervision

 Finally you decide Asset Deal <-> Share Deal

38

 SPV sells equipment at acquisition cost to you  SPV assigns license for target market to you  SPV assigns existing loan agreements to you

39

 You buy the shares in the fully licensed SPV  IMC grants you the right to assign the rights

pertaining to the SPV.

 Then you can decide

how you transfer the modular production line best

 or f.e. keep the SPV for acquisition and

trading purposes

40

People Function 1 Quality control reception 2 Operator Coating Machines 2 Assembly 1 Packaging 1 Quality Control 1 Supervisor- Production Coordinator 1 Logistic – supply chain

41

IMC International Medical Contrivances S.A. 25 Montée de Clausen L – 1343 Luxembourg Contact: Gerd Schneider Director +352 661 65 11 17 Mail :g.schneider@azurfive.com

42